London November, 27 th 2010

Transcription

1 PHYSIOLOGICAL REGULATING MEDICINE IN YOUR PRIMARY CARE Otolaryngology Cold and Flu Immune Immuneand autoimmune disorders Sexual disorders and sexual wellness London November, 27 th 2010

2 This material is based on the presenter s studies in PHYSIOLOGICAL REGULATING MEDICINE. The information presented here is not to be considered a prescription p and we do not accept medical or legal responsibility for misuse of the information presented. This information is for educational purposes for licensed health care professionals within their scope of practice. 2

3 Save your time! Tk Take your DIPLOMA of Specialist in Physiological Regulating Medicine

4 The pathway we ll take START TheScientific basis of Physiological Regulating Medicine TheMechanism of action of biotherapeutic medicine ingredients FINISH SYMPTOM PNEI P.N.E.I. TREATMENT REBALANCING THROUGH SPECIFIC DRUG FOR ORGAN OR DISEASE DRAINAGE AND DETOXIFICATION

5 CROHN DISEASE IL10 4CH: 20 drops twice a day for 4 6 months ANTI IL1: 20 drops twice a day for 4 6 months IL4 4CH: 20 drops twice a day for 4 6 months GUNA G MOOD: 20 drops twice a day for 4 6 months COLOSTRO NONI: 2 sachets ht a day for 1 2 months GUNA FLAM: 20 drops twice a day for 4 6 months GUNA BOWEL: 20 drops twice a day for 4 6 months 5

6 Physiological Regulating Medicine PRM WESTERN CONVENTIONAL MEDICINE LOW DOSE MEDICINE 6

7 PRM DRUGS A new pharmacological concept: one biotherapeutic medicine blending synergistic ingredients from Complementary Alternative Medicine and Conventional Medicine to achieve a positive clinical outcome. Molecular Biology NEUROPEPTIDES, CYTOKINES, HORMONES, GROWTH FACTORS Homeopathic Science MINERAL, PLANT, ANIMAL DERIVATIVES

8 PHYSIOLOGICAL REGULATING MEDICINE (PRM) The science of PRM integrates state of the art scientific advances in: Homeopathy Homotoxicology Psycho Neuro Endocrine Immunology (PNEI) Nutritional Medicine To formulate biotherapeutic medicines achieving the best individualized prescription for patients t to promote recovery from illness and restoration ti of health Dipartimento Scientifico Guna S.p.a. PNEI P.N.E.I. Molecular Biology Nutritional Medicine Homeopathy Homotoxicology Quantum Physics

9 Physiological Regulating Medicine PRM PRM codifies the vision of the organism as a psycho-neuroendocrine-immune NETWORK regulated by mechanisms of FINE CONTROL (sensitive ligandreceptor control mechanisms) 9

10 Homeostatic control systems P N E I CENTRAL NERVOUS SYSTEM & NEUROVEGETATIVE SYSTEMS ENDOCRINE SYSTEM IMMUNE SYSTEM Ader, R., Psychoneuroimmunology, IV edition, vol. 1 e 2, Academic Press, Amsterdam It is the classical text on the matter, pubblished for the first time in 1981.

11 PSYCHE P.N.E.I. NETWORK AND MESSENGER MOLECULES P NEUROPEPTIDES N HORMONES E HORMONES I INTERLEUKINS SOMA I E N P PSYCHE

12 Messenger Molecules The Foundation for PRM COMMUNICATING MOLECULES are messengers, the words used by the 3 homeostatic control systems to speak each other and to understand d each other. 12

13 P.N.E.I. NETWORK AND MESSENGER MOLECULES EVERY DISEASE IS THE EXPRESSION, THE CONSEQUENCE OF CHANGED CONCENTRATION OF MESSENGER MOLECULES 13

14 DISEASE HYPER CONCENTRATION 10 6 HALH HEALTH C X6 PHYSIOLOGICAL CONCENTRATION HYPO CONCENTRATION DISEASE

15 DEFINITIONS g (gram)= = = mg (milligram)= 10-3 = μg (microgram)= 10-6 = ng (nanogram)= 10-9 = pcg (picogram)= = fg (fentogram)= =

16 Importance of the Connective Tissue (EXTRA-CELLULAR MATRIX) in Physiological Regulating g Medicine With Physiological Regulating Medicine (The Guna Method) we overcome the concept of a static matrix. The Connective Tissue: MORPHO-FUNCTIONAL UNITY CAPILLARY MATRIX MEMBRANE RECEPTORS 16

17 -MEMBRANE RECEPTORS MATRIX VESSELS THE CONNECTIVE TISSUE Morpho o-functional unity: vessel-m matrixmembrane receptor

18 The Connective tissue in PHYSIOLOGICAL REGULATING MEDICINE. 1 The Connective tissue is the true System of basal Regulation : all the changes in our external and internal environment influences, through the ground substance, cellular mechanisms. Communication between cells and the external environment takes place through the matrix: a vast quantity of information can be stored in the matrix and transmitted to the cells as instructions for their physiologic activity. The neurovegetative endings branch out in the matrix; it s here that, through neural peptides, endocrine hormones and cytokines, the psycho-neuro-endocrine-immunologic information is transmitted, which h coordinates and controls ol its activity it by means of messenger molecules binding with the cell receptors. The accumulation of stressors (physical or biochemical) in this place represents the potential trigger for the beginning and the progression of pathologic processes. 18

19 The Connective tissue in PHYSIOLOGICAL REGULATING MEDICINE. 2 The membrane receptor plays a KEY role. The quantity of ligand (hormone, cytokine or neurotransmitor) and the receptor s ability to bind these molecule l (including the the ligand s affinity to the receptor) are both critical to the process of communication. Good examples are leptin in obesity, insulin in type 2 diabetes (non-insulin-dependent) or TNF-alpha or IL-1 in chronic inflammation. ONLY physiologic concentrations are able to activate or reactivate the membrane receptors and consequently, stimulate the physiologic function of a target cell. 19

20 Physiological Regulating Medicine: a dynamic new concept PRM starts from the revolutionary therapeutic concept of restoring physiology through h administration i ti of communicating molecules-hormones, interleukins, neuropeptides and growth factors-prepared in homeopathic dilutions, which are equivalent to the physiologic concentrations found in the human body (biological milieu) 20

21 Why homeopathically prepared? The homeopathic preparation p method of dilution-dynamization makes these communicating molecules even more effective. 21

22 COHERENCE EFFECTS IN WATER O H H O H H O H H O O H H H H Ordinary water With SKA they onset the di Frölich phenomenon: all the water dipoles become in series instead of chaotic, that brings to the reduction of dielectric Constant, that is a easier electromagnetical Transmission. O O O H H H H H H Biological water 22

23 S.K.A SKA It is a smart DRUG DELIVERY SYSTEM able to make a molecular concentration effective below that of the standard minimal effective dose.

24 EFFECTS OF DIFFERENT DOSES OF CYTOKINES TM TOXIC CONCENTRATION 10 3 mg/ml TOXIC EFFECT PHARMACOLOGICAL EFFECTS PHARMACOLOGICAL CONCENTRATION mcg/ml 10 6 MINIMAL EFFECTIVE PHARMACOLOGICAL DOSE SIDE EFFECTS WITH DYNAMIZATION: PHYSIOLOGICAL EFFECTS PHYSIOLOGICAL CONCENTRATION ng pcg/ml WITHOUT DYNAMIZATION: NO BIOLOGICAL Or PHYSIOLOGICAL EFFECTS MINIMAL EFFECTIVE PHYSIOLOGICAL DOSE 24

25 in cooperation with: Effects of different dosesofof IL 1 β on isolated human fibroblasts 25

26

27 Expression of NFKb on isolated fibroblasts nfkb lps a c d b lps a c d b 1h 18h Legend lps=control A=placebo (water and alcohol) B=pharmacological concentration C=4CH diluted and SKA D=4CH only diluted but not SKA

28 How to use the messenger molecules THE SCALES OF THE BODY

29 THE IMMUNE SYSTEM Th1 Th

30 Th 1/Th 2 BALANCE Th1 UP REGULATION Th 2 Th2 UP REGULATION IL 12 IFN γ Th 2 Th 1 IL 4 IL 5 Crohn s Disease Psoriasis IL 4 IL 5 IL 12 IFN γ Asthma Atopy Th2 DOWN REGULATION Th1 DOWN REGULATION 30 30

31 in Allergy Th2 IL 4 4 Th1 IL 5

32 in Pain Th1 IL 1 TNF αα Th2 IL 6

33 in Crohn s disease Th1 TNF α IFN γ IL 17 IL 12 IL 8 8 Th2

34 STIMULATES Th0 STIMULATES IL 12 IL 4 Th1 Th2 INF γ, IL 12 IL 4 INHIBITS INHIBITS INF γ THE CONCEPT OF BALANCE Developing Th subsets results in cross regulation. While IL 4 stimulates Th2 differentiation and inhibits diffentiation of Th1 cells, IL 12 and IFN γ stimulates Th1 differentiation and inhibits the development of Th2 cells. Cooke, A. Th17 in Inflammatory Conditions. 2006, Rev Diabetic Stud 3: 72 7 Bettelli E. et al. Th17: The third member of the effector T cell trilogy. Current Opinion in Immunology 2007, 19:

35 THE CONCEPT OF BALANCE USING SKA ACTIVED PHYSIOLOGIC DOSE CYTOKINES Th subsets cross regulate the expansion and functions of one another. IL 4 stimulates Th2 differentiationi i and inhibits differentiationi i of Th1 cells and IFN γ stimulates Th1 differentiation and inhibits the development of Th2 cells, while both cytokines inhibit the development of Th17. Bettelli E. et al. Th17: the third member of the effector T cell trilogy. Current Opinion in Immunology 2007, 19:

36 in cooperation with: Effects of low dosecytokinesintreatment treatment of inflammatory pathologies: use in an animal model of allergic asthma 36

37 Low dose oral administration of cytokines for treatment of allergic asthma Volume 22, Number 6, pp , December 2009 Silvia Gariboldi, Marco Palazzo, Laura Zanobbio, Giuseppina F Dusio, Valentina Mauro, Umberto Solimene, Diego Cardani, Martina Mantovani, Cristiano Rumio and S.G.M.P. contributed equally to this work Reviewer e e #1: INTRIGUING G WORK: Low dose oa oral administration at of IL 12 plus IFN gamma for treatment in murine model of allergic asthma. solve BHR. Anti asthmatic activity for 8 15 days confirmed by histological analysis of lungs and balfluid cell count, it is convincing for this murine model. Serum OVA specific IgE also inhibited by this low dose activated cytokines solution, SUGGESTING A NOVEL APPROACH.

38 EXPERIMENTAL PROTOCOL LUCKY MOUSE DAY 1 DAY 7 DAY 13 Injection of 1 mg of egg albumin + 5 mg Al(OH) l( )3 in PBS (IP) Injection of 1 mg of egg albumin + 5 mg Al(OH) l( )3 in PBS (IP) Aerosol of 1 mg of egg albumin + 5 mg Al(OH) l( )3 in PBS TREATMENT WITH IL 12+IFN γ from DAY 18 until DAY 38 Blood drawing DAY 38 Bronchoalveolar lavage fluid DAY 30 5% egg albumin in PBS 0,5. (Aerosol) ALLERGIC MOUSE DAY 27 Injection of 1 mg of egg albumin + 5 mg Al(OH)3 in PBS (IP)

39 Asthma Th1 BALF after treatment with egg albumin and Al (OH) 3 Th2 180 Legend Untr=healthy mouse 2 OVA=allergic mouse [IL 4] (pc cg/ml) [IL 5] (p pcg/ml) UNTR OVA UNTR OVA

40 IL-4 pg/m ml Level of IL 4 and IL 5 in mice sera on day 7 th of treatment Levels of IL 4 Treatment plan of allergic mouse with the 2 anti allergic interleukines in association (IL 12+IFN γ) Legenda 1 Untr=healthy mouse 2 OVA=allergic mouse 3 OVA+ALLO=IL 12+IFN γ in pharmacological concentration 4 OVA+4CH=IL 12+IFN γ4 4CH IFN in physiological i lconcentration ti (4CH) diluted and dinamized 5 OVA+4CHn=IL 12+IFN γ in physiological concentration (4CH) only diluted but not dinamized 180 Levels of IL Untr OVA OVA+Allo OVA+4CH OVA+4CHn OVA+30CH IL-5 pg/ml Untr OVA OVA+Allo OVA+4CH OVA+4CHn OVA+30CH

41 Level of IL 12 and INF γ in mice sera on day 7 th of treatment Treatment plan of allergic mouse with the 2 anti allergic interleukines in association (IL 12+IFN γ) Legenda IL-12 pg/m ml Levels of IL 12 1 Untr=healthy mouse 2 OVA=allergic mouse 3 OVA+ALLO=IL 12+IFN γ in pharmacological concentration 4 OVA+4CH=IL 12+IFN γ in physiological concentration (4CH) diluted and dinamized 5 OVA+4CHn=IL 12+IFN γ in physiological concentration (4CH) only diluted but not dinamized Level of IFN γ Untr OVA OVA+Allo OVA+4CH OVA+4CHn OVA+30CH IFNgam mma pg/ml Untr OVA OVA+Allo OVA+4CH OVA+4CHn OVA+30CH

42 Unit of measurement the mystery that is not a mystery we give we dt detect tin the blood fg 4CH 1 fg/mouse pg

43 Eosinophilnumbers numbers inmouse BALF (bronchoalveolar lavage fluid) on day 20 of treatment UNTREATED 0 OVA=CONTROL (ALLERGIC MOUSE) 20,188±0,613 OVA+ALLO ALLO (PHARMACOLOGICAL TREATMENT) 0 OVA+4 CH (4 CH SKA ACTIVITED TREATMENT) 0 OVA+4 CH n (4 CH not SKA ACTIVITED ACTIVITED TREATMENT) 19,567±0,685 OVA+30 CH (30 CH SKA ACTIVITED TREATMENT) 20,788±0,416 Number of cells expressed in cells/balf (x10 4 )

44 Safety of clinical use of SKA treated low doses of interleukines Preliminary datas IL-12 IFN-g g/ml) [IL-12] (p 30, , ,00 15,00 10,00 5,00 0,00 Untr OVA+100ng/die OVA+4CH din [IFNgamma a] (pg/ml) Untr OVA+100ng/die OVA+4CH din

45 Regulation of Th1 Th2 balance. IL 12 4C INF γ 4C Vincetoxicum 6X Regulation of allergic diasthesis. Sulphur 12/30/200X Natrum sulphur. 12/30/200X Mn-gluconate 4X Regulation of allergic metabolic status. Citricum ac. 6X Natrum pyruvicum 6X Succinicum ac. 6X Modulation of allergic symptoms: edema, redness, itching. Black currant bark 1x Viburnum opulus T Histaminum 12/30/200X Sulphur 12/30/200X Specific desensitization to Compositae*, Grass** and Urticaceae*** families. SYMPTOM CONTROL TREATMENT OF ALLERGIC TERRAIN NON-SPECIFIC DESENSITIZATION SPECIFIC DESENSITIZATION Ambrosia artemisiae folia 18X** Wyethia helenioides 18X** Phleum pratense 18X* Arundo mauritanica 18X* Urtica urens 18X*** Parietaria officinalis 18X*** Histaminum 12/30/200X Serum anguillae 12/30/200X Increase of basophil and mast cell tolerance toward allergic stimuli GUNA-ALLERGY ALLERGY 45 PREV

46 RESPIRATORY ALLERGY THERAPY ACCORDING TO THE PRM TRIANGLE OF THERAPY GUNA ALLERGY PREV: 20 drops twice a day for 2 4 months GUNA ALLERGY TREAT: 20 drops twice a day for 2 4 months. As shock therapy: 10 drops every 30 for 2 hours GUNA RHINO NOSE SPRAY: 2 sprays in each nostril 4 5 times a day; Acute phase: 2 sprays in each nostril every 30 for 2 3 hours (allergic rhino conjunctivitis) GUNA MATRIX: 20 drops twice a day for 2 4 months + GUNA BOWEL: 20 drops twice a day for 2 4 months (especially for allergic asthma) 46

47 in cooperation with: Effects of low dose cytokines (Anti IL 1 α and β; IL 10) in treatment of inflammatory pathologies: use in an animal model of CROHN S DISEASE 47

48 Cytokines levels IL 12* IFN γ IL-12 pg/ml /ml IFN pg Dipartimento Scient tifico Guna S.p.a Untr DSS DSS+Allop DSS+4HC OM DSS+4CH non OM Untr DSS DSS+Allop DSS+4HC OM DSS+4CH non OM TNF α* IL TNF pg/ml KC pg/ml Untr DSS DSS+Allop DSS+4HC OM DSS+4CH non OM Untr DSS DSS+Allop DSS+4HC OM DSS+4CH non OM

49 Cytokines levels 2000 IL 17 IL-17 pg/m ml Untr DSS DSS+Allop DSS+4HC OM DSS+4CH non OM IL 10 Legenda: 1: values in healthy mouse 2: values in mouse with Crohn s 3: values in the mouse with Crohn s after 7 days tretment with Anti IL 1+IL 10 at phamacological dosages 4: : values in the mouse with Crohn s after 7 days tretment with Anti IL 1+IL 10 at 4CH concentration SKA 5: values in the mouse with Crohn s after 7 days tretment with Anti IL 1+IL 10 at 4CH concentration not SKA IL-10 pg/ml Untr DSS DSS+Allop DSS+4HC OM DSS+4CH non OM

50 ZONA OCCLUDENS 1 and OCCLUDIN) DSS (dextran sodium sulfate) BEFORE TREATMENT Anti IL 1+IL 10 4CH AFTER TREATMENT 60 x

51 Colon length cm) co olon length ( 12 Legenda: 1: lenght of the colon 10 affected by Crohn s treated with placebo 8 2: lenght of the colon affected by Crohn s treated with Anti 6 IL 1+IL 10 at pharmacological dosage 4 3: lenght of the colon affected by Crohn s treated with Anti 2 IL 1+IL 10 4CH SKA : lenght of the colon affected 0 by Crohn s treated with Anti IL 1+IL 10 4CH not SKA hydroalcoholic solution allopathic homeopathic nn homeopathic

52 Colon resistance Ω*c cm 2 Legenda: 1: resistance of the colon 60 affected by Crohn s treated with placebo 50 2: resistance of the colon 40 affected by Crohn s treated with Anti IL 1+IL 10 at 30 pharmacological al dosage 3: resistance of the colon 20 affected by Crohn s treated 10 with Anti IL 1+IL CH SKA : resistance of the colon 0 affected by Crohn s treated with Anti IL 1+IL CH not SKA 5: resistance of the colon in healthy mouse hydroalcoho oalcoholic solution allopathic homeopathic nn homeopathic ctrl

53 Interpretazione dell immagine Nell immagine, ottenuta in immunoflluorescenza, si osserva a sinistra una cripta intestinale trattata con dextran sodium sulfate, capace di distruggere le proteine intra ed extra cellulari delle tight junctions (occludina e zona occludens) e di provocare un quadro anatomo patologico assimilabile al Crohn. Si osservino in rosso le cellule epiteliali disorganizzate e staccate dalla lamina basale. Nell immagine di sinistra si osservano le cellule epiteliali di una cripta intestinale sottoposta allo stesso trattamento sperimentale con dextran sodium sulfate ma alla quale è stata aggiunta la miscela di Anti IL 1 4CH + IL 10 4CH. Le cellule epitieliali sono perfettamente intatte e adese alla lamina basale. L effetto protettivo dell associazione di Interleuchine a bassi dosaggi fisiologici attivati è eclatante lt t e lascia supporre una possibile applicazione i clinica i quantomeno nel rallentamento della progressione della patologia.

54 The concept of BALANCE and the use of the cytokines. Th1 Th3 Th2 PRO INFLAMMATORY TOLERANCE ANTI INFLAMMATORY GCSF IL1 IL2 INF-gammma IL6 IL8 TNF-alfa IL12 TGF-ββ IL10 IL10 TGF beta IL4 IL5 IL6 IL7 IL9 IL13 54

55

56 MOUNTAIN CRANBERRY 3X ANANASSA SATIVA 3X HYDROCOTYLE ASIAT. 3X CITOMIX LYMPHATIC VESSEL 4C MEDULLA OSSIS SUIS 4C THYMUS GLAND 4C ANTISEPTIC ACTION (Mountain cranberry) ANTI-INFLAMMATORY (Ananassa sativa) RES STIMULATING (Hydrocotyle asiatica) ORGAN PREPARATIONS HOMEOPATHIC SUIS REMEDIES HOMEOPATHICALLY DILUTED CYTOKINES STIMULATION OF IMMUNOCOMPETENT TISSUES TRIGGER IMMUNE RESPONSE GCSF 4/9/15 C IL-1 5C INF gamma 4C IL-4 4C IL-2 5C STIMULATION OF B (IL-4) and T, B, NK (IL-2). IL-6 7/9/15C 56

57 BLOOD DRAWING Ospedale San Raffaele Milano Laboraf Diagnostica e Ricerca San Raffaele (Direttore Michelangelo Murone) % LINF. T (CD3) 58.8% 60.2% LINF. T (CD4) % LINF. T (CD8) % RAPPORTO CD4/CD8 LINF. T (CD3) cell./ul cell./ul +15,6 LINF. T (CD4) cell./ul cell/ul +11,8 LINF. CD cell./ul cll./ul +31,1

58 Regulation of the extracellular matrix function through the modulation of the hypophysary hormons action and the pineal gland stimulation. Melatonin 4C Hypophysis porcine 200X Pineal Gland 6X Conjunctive tissue 12X The 3 pillars in a drug Hepar sulfuris Pyrogenium Ferrum phosphoricum GUNA-FLAM Aconitum* Beta-endorphin** Aconitum* Belladonna* Ferrum phosphoricum* Apis* Bryonia* Pyrogenium* Phytolacca* Natrium pyruvicum* Acidum citricum* Cu-gluconate* Anti IL 1-alfa** TGF 1 beta*** IL 10*** Modulation of the neurogenic, vasal exudative phases of the inflammatory process*. Hindrance to the inflammation start point**. Potentiation of the immunologic anti- inflammatory activity having Th2-Th3 polarity***. RES stimulation and hindrance to the possible septic progression of the inflammatory process. Modulation of the neurogenic phase of inflammation*. Sensitization of the beta-endorphin peripheral receptors**.

59 Cytokines and Growth Factors of PRM INF α IL10 NGF INF γ IL11 NT3 IL1 IL12 NT4 IL2 IL3 PDGF BDNF IL4 IL5 GCSF TGF ββ CNTF EGF IL6 IL7 IL8 IL9 TNF α FGF G1 IGF 1

60 The concept of BALANCE and the use of the cytokines. Th1 Hypercativation Diseases Th2 Hypercativation diseases Rheumatoid Arthritis (IL1, IL6, IL2, TNF-α, IL17) Multiple Sclerosis (IL12, INF, TNF-α) Diabetys type I (IL1, TNF-α, INF-γ, IL17) Tubercolosis (IL12, IL18) Autoimmune endocrine pathologies Allergy (IL4-IL5-IL13) Asthma (IL4-IL10) Atopic dermatitis (IL4-IL10) IL10) Sclerodermia (IL17-IL6) HIV IBD (IL1, IL6, TNF-α, IL23, IL17)

61 Relationship between hormones and cytokines The hormones influence cytokines levels and realize a connection between endocrine system and immune system FEMALE SEXUAL HORMONES O inhibit btthe Th2 reaction and stimulate Th1 cytokines CORTISOL inhibit Th1 reaction and in particular IL 2. In turn, different interleukins, among which IL 1, IL 6, TNF α, IFN stimulate ACTH secretion and therefore also cortisol secretion

62

63 PCO PROGESTERON D6: 20 drops twice a day from the 14 day to 21 day, for 2 4 months + FSH D6: 20 drops twice a day from 1 to 7 day of period for 2 4 months (for the reverse of the relationship LH/FSH) GUNA FEM: 20 drops twice a day for 1 month of therapy continue with G3: 20 drops twice a day from the 2 month of therapy MELATONIN 4CH: 20 drops at evening every day for 2 4 months GUNA LYMPHO: 20 drops at evening every day for 2 4 months 63

64 Hormones of PRM Hypothalamus Somatostatine Beta Endorphin Hypophysis FSH LH ACTH Prolactin TSH Pineal Gland Melatonin Thyroid TSH Triiodohyronine (T3) Thyroxine (T4) Calcitonin Parathyroids Parathormone (PTH) Ovary Beta Estradiol Progesterone

65 Neuropeptides pp of PRM Hypothalamus e Hypophysis p y Beta Endorfin Nucleus of rafe of Bulbo, of Bridge and of Mesencefalo. Stomach and bowel Serotonin Pineal Gland Melatonin

66 GUNA METHOD PHARMACOLOGY 66

67 P.R.M. bag of tools From Homeopathy Plants AnimalsA i l Minerals From Homotoxicology Catalysts Nosodes Suis organ preparations From Nutrition Therapy Trace elements Vitamins Nutrients From P.N.E.I. Hormones Interleukins Neuropeptides Growth factors

68 Regulation of the extracellular matrix function through the modulation of the hypophysary hormons action and the pineal gland stimulation. Melatonin 4C Hypophysis porcine 200X Pineal Gland 6X Conjunctive tissue 12X The 3 pillars in a drug Hepar sulfuris Pyrogenium Ferrum phosphoricum GUNA-FLAM Aconitum* Beta-endorphin** Aconitum* Belladonna* Ferrum phosphoricum* Apis* Bryonia* Pyrogenium* Phytolacca* Natrium pyruvicum* Acidum citricum* Cu-gluconate* Anti IL 1-alfa** TGF 1 beta*** IL 10*** Modulation of the neurogenic, vasal exudative phases of the inflammatory process*. Hindrance to the inflammation start point**. Potentiation of the immunologic anti- inflammatory activity having Th2-Th3 polarity***. RES stimulation and hindrance to the possible septic progression of the inflammatory process. Modulation of the neurogenic phase of inflammation*. Sensitization of the beta-endorphin peripheral receptors**.

69 What from Homeopathy The study of pharmacological effects of homeopatyzed PLANT, MINERALS and ANIMALS PRINCIPLES on healthy humans and their usage depending on the principle of similarity and effect inversion in an ill subject.

70 THE 3 MAIN PRICIPLES OF HOMEOPATHY

71 The Science of Homeopathy basic assumptions Law of Arndt Schultz (Law of inverse effect ) Weak stimulus activates biological functions Medium stimulus modulates biological functions Strong stimulus inhibits biological functions Very strong stimulus blocks biological functions

72 Effects of high dose Strycnos Nux vomica on acetylcholine receptors of gastric mucosa parietalcells + HCl (hydrochloric acid) + proton pomp Parietal cell of gastric mucosa Acetylcholine receptor acetylcholine parasympathetic fiber Increased excitability of parasympathetic fibers High dose Strycnos Nux vomica

73 Effects of homeopathic dose Strycnos Nux vomica on acetylcholine receptors of gastric mucosa parietal cells HCl (hydrochloric acid) proton pomp Parietal cell of gastric mucosa Acetylcholine receptor Acetylcholine parasympathetic fiber Decreased excitability of parasympathetic fiber Homeopathic dose Strycnos Nux vomica

74 What from: ESSENTIAL POINTS OF THE THERAPY HOMEOPATHY AND HOMOTOXICOLOGY A) FUNCTIONAL RECOVERY B) NEUTRALIZATION OF ETIOLOGIC CAUSES Connective and vicariant emunctory DRAINAGE Methabolic restoration (CATALYSTS) NOSODE immunotherapy C) RESTITUTIO AD Tissue recovery ( SUIS INTEGRUM OF THE INJURED ORGAN TISSUE PREPARATIONS)

75 CLINICAL CONSEQUENCES OF COMPROMISED ENZYMATIC ENERGY PATHWAYS OF KREBS' CYCLE Chronic Pathologies Pyruvate Allergy Citrate Recurent Pathologies Oxaloacetate Cis Aconitase Stress Intoxication Fumarate Mg Mn alpha- ketoglutarate Neuro Muscolar Pathologies Iporeactivity Malate P Baryum oxalsuccinicum Endocrine aging Anaemia Succinyl - CoA

76 NOSODES -1 PATHOLOGIC MATERIAL (Secretions Excretions Morbid tissues Microbial cultures) NOSODES RES 70% Iceberg Phenomenon CELL-MEDIATE IMMUNE RESPONSE AIMED AT (SPECIFIC) AND LIMITED TO THE PATHOGENIC AGENT

77 IMMUNESTIMULATION CORE Prevention and treatment of flu and cold syndromes SYMPTOMATIC CORE

78 SUIS ORGAN PREPARATIONS SWINE TISSUES OR ORGANS (Immunologic similarity between Suis and Homo ) SUIS ORGAN PREPARATIONS ORGAN OR TISSUE TARGET ASPECIFIC AND LIMITED TO THE TARGET (ORGAN OR TISSUE) IMMUNE RESPONSE 70% Iceberg Phenomenon

79 HYPOPHYSIS Glandular function stimulation by means of immunologic i mechanisms. GLAND Risultato terapeutico TSH Hypophysis suis FSH GH ACTH D6/D30 LH PRL Guna S.p.a. Scientific Department

80 HOMEOPATHIC ORGANOTHERAPY Homeopathic Organotherapy, the use of Sarcodes, works on the premise that: 1. A Homeopathic potenized gland/organ acts upon its corresponding gland/organ. 2. Low potencies stimulate 3. High potencies slow down 3. According potencies regulate

81 What from HOMOTOXICOLOGICAL PHARMACOLOGY for the P.R.M. THERAPEUTICSTRATEGY? Catalysts METABOLIC STIMULI Nosodes IMMUNE STIMULI Suis organ preparations FUNCTION REGULATION

82 1 ST GUNA PHARMACOLOGY PRINCIPLE SYNERGISM GUNA COMPLEXES BALANCE COMPLETENESS 82

83 SYNERGISM: the ingredients work together synergistically. The global effect is greater than the summation of the effects of individual id ingredients. BALANCE: The ingredients are present in quantities and dilutions to promote restoration and re-balancing balancing, without negatively impacting psycho-neuro-endocrine-immune homeostasis. COMPLETENESS: the ingredients are combined so that every step of the etiopathogenetic cascade and every possible symptomatologic expression of the pathology that the drug is indicated for is taken into account. 83

84 2 nd GUNA PHARMACOLOGY PRINCIPLE THE ETIOPATHOGENIC PROCESS OF THE PATHOLOGY BEING TREATED IS INSCRIBED WITHIN THE HOMEOPHARMACOLOGIC STRUCTURE OF THE GUNA METHOD COMPLEX BIOTHERAPEUTIC MEDICINES 84

85 Medications Alcohol Infections Food toxicity Alteration ti of acid secretion Gastric mucosal inflammation Peptic ulcer Chronic gastritis Pyrosis/heartburn Acidity Gastric and epigastric symptoms Catarrh Reaction/excess mucous production 85

86 EGF 4C Stimulation of mucosal epithelium with compensation for histologic damage caused by acid hypersecretion Regulation of acid secretion 1 Dopamine 6X Sympathetic nerve 3/6/12X Origanum 6/10/30X Ipeca 8/30/200x Reduction of HCl secretion from the cell wall due to reduction of vagotonic activity following a sympatheticotonic stimulation. Histologic i Protection ti of the mucosa Antimonium crudum 6/12/30/200X Reduction of gastric mucus which is a possible pabulum for the proliferation of Helicobacter pylori 4 GUNA STOMACH 3 Regulation of the mucous reaction 2 Reduction of inflammatory gastricand ti and epigastric i symptoms Argentum nitr.6/12/30/200c* Dioscorea vill. 3X* Carbo veg. 6X* Robinia 2X* Stomach 30/200X* Momordica 3X* Abies nigra 3X* Bismuthum subn. 6X** Anacardium 6/12/30/200** Control of the local phlogosis phenomena of the gastric mucosa and of the gastric symptoms*: pyrosis, acidity, gastric tympanism (due to absorption of putrefactive toxins: Carbo v.); 86 epigastralgy**

87 GUNA METHOD THERAPEUTIC STRATEGY 87

88 The PRM Therapeutic Triangle P.N.E.I. REPROGRAMMING REMEDY SPECIFIC REMEDY FOR ORGAN OR DISEASE DRAINAGE REMEDY 88

89 STRATEGY FOR GENERAL NEURO-ENDOCRINE REBALANCING MALE SUBJECTS GUNA-MALE FEMALE SUBJECTS GUNA-FEM 89 Dipartimento Scientifico Guna S.p.a.

90 Regulation of thymic hormone synthesis (immune system strengthening) THYMUS GLAND Regulation of cortisol and catecholamine synthesis (greater stress resistance). Stimulation i l i of sex hormone synthesis GLANDULA SUPRARENALIS SUIS NEURO-ENDOCRINE REPROGRAMMING PINEAL GLAND MELATONIN HYPOTHALAMUS HYPOPHYSIS camp GUNA- FEM Regulation of thyroid hormones (irregular under stress conditions) PANCREAS SUIS Regulation of insulin response (irregular under stress conditions) OOPHORINUM CORPUS LUTEUM SUIS LILIUM THYROIDINUM Stimulation of gonad function in women 90

91 Regulation of thymic hormone synthesis (immune system strengthening) THYMUS GLAND Regulation of cortisol and catecholamine synthesis (greater stress resistance). Stimulation i l i of sex hormone synthesis GLANDULA SUPRARENALIS SUIS NEURO-ENDOCRINE REPROGRAMMING PINEAL GLAND MELATONIN HYPOTHALAMUS HYPOPHISIS camp GUNA- MALE Regulation of thyroid hormones (irregular under stress conditions) PANCREAS SUIS THYROIDINUM Regulation of insulin response (irregular under stress conditions) ORCHITINUM DAMIANA Stimulation of gonad function in men 91

92 STRATEGY FOR GENERAL IMMUNE-ENDOCRINE REBALANCING MALE SUBJECTS GUNA-MALE + CITOMIX FEMALE SUBJECTS GUNA-FEM + CITOMIX 92 Dipartimento Scientifico Guna S.p.a.

93 MOUNTAIN CRANBERRY 3X ANANASSA SATIVA 3X HYDROCOTYLE ASIAT. 3X CITOMIX LYMPHATIC VESSEL 4C MEDULLA OSSIS SUIS 4C THYMUS GLAND 4C ANTISEPTIC ACTION (Mountain cranberry) ANTI-INFLAMMATORY (Ananassa sativa) RES STIMULATING (Hydrocotyle asiatica) ORGAN PREPARATIONS HOMEOPATHIC SUIS REMEDIES HOMEOPATHICALLY DILUTED CYTOKINES STIMULATION OF IMMUNOCOMPETENT TISSUES TRIGGER IMMUNE RESPONSE GCSF 4/9/15 C IL-1 5C INF gamma 4C IL-4 4C IL-2 5C STIMULATION OF B (IL-4) and T, B, NK (IL-2). IL-6 7/9/15C 93

94 STRATEGY FOR GENERAL NEURO-ENDOCRINE REBALANCING MALE SUBJECTS GUNA-MALE + GUNA-MOOD FEMALE SUBJECTS GUNA-FEM + GUNA-MOOD 94 Dipartimento Scientifico Guna S.p.a.

95 Melatonin synthesis and consequent regularization of NEURO-ENDOCRINE HOMEOSTASIS (neuro-endocrine Reprogramming) GUNA-MOOD Indirect regulation of hypothalamic activity AVENA SATIVA ALFA ALFA Antiasthenic and neurotonic action Similarity to typhus (depression, confusion, delirium) SALMONELLA TYPHI PINEAL GLAND THYMUS GLAND SEPIA ACIDUM PHOSPHORICUM IGNATIA LACHESIS SYNERGISM SALIX Psychastenia (Ac. Phosphoricum) helps depression with irritability (Sepia) TRYPTOPHAN HYDROXYTRYPTOPHAN SEROTONIN Restoration of balance in Mood with serotonergic activity i 95

96 ANTI-AGE AGE STRESS Action against free radicals*. Action against brain degeneration**. n-acetyl cysteine* 4C Glutathione* 4C Kali carb.** 9C Thalamus, porc. 7C Stomach, porc. 7C Cortex cerebralis, porc. 4/7C Melatonin 4/15C Adrenalinum 9/15C Plexus solaris 7C ANTI- DEGENERATIVE CORE P.N.E.I. REBALANCE (1) SYMPTOMATIC CORE P.N.E.I. REBALANCE (2) Neuro-endocrine endocrine axis reprogramming. G.C.S.F. 4C Interferon gamma 5C Sporobolomyces gr. 8X Penicillium not. 8X Anti-anxiety action *. Anti-stress action**. Mood stabilization***. Argentum nitr.* 9C Citrus decumana* 3X Black horehound * 3X Nux vomica** 5/7/9/15C Lithium carb.*** 8X Immune-endocrine endocrine axis reprogramming. 96

97 P.N.E.I. REPROGRAMMING DIRECTIONS GUNA FEM: 20 drops twice a day for at least 2 months GUNA MALE: 20 dropstwicea day for at least 2 months CITOMIX: 10 pellets once a week for at least 2 months GUNA MOOD: 20 dropstwicea day for at least 2 months ALL THE A M PRODUCTS CAN BE TAKEN TOGETHER (for example ALL THE A.M. PRODUCTS CAN BE TAKEN TOGETHER (for example putting drops of each medicine in 1 litre bottle of water. The patient drinks this bottle during the whole day)

98 2 DRAINAGE STRATEGY EMUNCTORY DRAINAGE MATRIX DETOXIFICATION CELLULAR DETOXIFICATION 98 Dipartimento Scientifico Guna S.p.a.

99 Anatomic Structure Action Drug CELL CELL DRAINAGE GUNA-CELL MATRIX MATRIX DRAINAGE GUNA-MATRIX GUNA-LYMPHO EMUNCTORIES EMUNCTORIAL DRAINAGE GUNA-LIVER GUNA-KIDNEY GUNA-BOWEL 99 Dipartimento Scientifico Guna S.p.a.

100 SYMPTOMS OF INTOXICATION Overweight/Obesity Skin rashes Itchy skin Anxiety and depression Sleepiness i Irritability Headache Poor concentration Low libido Fibromyalgia Widespread joint pain IBS (Irritable Bowel Syndrome) CFS (Chronic Fatigue Syndrome) MCS (Multiple Chemical Sensitivity Syndrome)

101 INDICATORS OF INTOXICATION LEVEL LEVEL III Alteration in structure and loss of function LEVEL II Reduction in function: hypertrophy and hyperplasia LEVEL I Inflammation and hyper-response response 101 Dipartimento Scientifico Guna S.p.a.

102 1 ST STAGE of INTOXICATION 2 ND STAGE OF INTOXIFICATION Inflammation & Hyperresponse Function reduction: hypertrophy and hyperplasia 3 RD STAGE OF INTOXIFICATION Loss of structure and function Dipartimento Scie entifico Guna S.p..a. GUNA-LYMPHO GUNA-LYMPHO GUNA-LYMPHO + + GUNA-MATRIX GUNA-MATRIX + GUNA-CELL DRAINAGE through a healthy PARALLEL ORGAN Good hepatic function: GUNA-LIVER Good intestinal function: GUNA-BOWEL Good renal function: GUNA-KIDNEY 102

103 Carrier action*. Reprogramming of cell function**. 2 nd function messenger***. Ac.-L-carnitine* 2X DNA** 6X RNA** 6X Collinsonia i 2X*** camp 6X*** Anti-degenerative and anti-aging action. Colchicum 6/12/30X Conium 6/12/30X Podophyllum 6/12/30X Methyglyoxal 10X GUNA CELL Vitamins Vit. E Vit. C Vit. B1, B2, B3, B5, B6, B9, B12 Coenzyme activity performing catalytic action on cell functions. α-lipoic-ac. 3X Succinic. ac. 3X Fumaric. ac. 3X Methyglyoxal 10X Increase of energetic metabolism. Mn-gluc. 3X Mn-phosph. 6X Mg-phosph. 3X P 4X Ca-gluc. 3X Fe fumar. 3X S 3X Se 3X Cu sulph. 3X Zn-gluc. 3X K-aspart. 3X Catalytic action on enzyme functions. 103

104 Deactivation (through inflammation) and neutralization of the impregnated toxins*. Pyrogenium 12X* Fucus 3X* Tyrosine T i 2X** Phenilalanine 2X** Histidine 2X** Synergistic action with Fucus and thyroid hormone activating the sympatheticotonic nervous system**. Hyaluronidase 6X* Thuja 6/8/12/30/200X** Natrium N t i sulfuricum 6/8/12/30/200X ** Prolactine 6X*** DHEA 6X*** Matrix hydrolysis* Action against the constitutional tendency to impregnation of the matrix with toxins and to the development of Dysmetabolic Mesenchymopathy (psychcosis).** Matrix solubilization.*** GUNA-MATRIX Action against toxin impregnation Lymphatic drainage Lymphatic vessel 6X Matrix liquification and drainage Inactive toxins mobilized towards the lymphatic circle for drainage Ac. D-L malicum 6X* Natrium oxal. 6X* Natrium pyruv. 6X* NADID 6X* Trychinoil 6X* Vit. C 2X* Ac. L(+) lacticum3x** Stimulation of mitochondrial energy production.* Matrix acidification (promoting connective tissue reactivity).** IL 6 4C* DHEA 6X* Pyrogenium 12X* Conjunctive Tissue 6X* Tyrosine 2X** Phenilalanine 2X** Histidine 2X** Prolactine 6X*** Increase of Fundamental Substance kinetics (protein hydrolysis, hyper-ionicity, histaminic activity, increased temperature) and matrix turnover rate.* Sympatheticotonic stimulation.** 104 Vagotonic inhibition.***

105 GUNA-LYMPHO Myosotis 3X Equisetum 3X Hydrocotile 1X Reduction R d i of local l Taraxacum 1X inflammation on lymphoepithelial tissues. Lymphatic vessel 6X Sarsaparilla 3X Capillary tisssue 6X Reduction of lymphatic L-Thyroxin 6/12X spasm due to Vein porcine 6X inflammation with restoration of the lymphatic circulation. REACTIVATION OF THE LYMPHATIC CIRCULATION Calendula 1X Phytolacca 3X Apis 8X Magnesia a phosph. 6/12/30/200X Stimulation of Humoral Immunity and inhibitory modulation of the excessive cell mediated compensatory response ANTI-INFLAMMATORY INFLAMMATORY HYPERTROPHY ACTIVITY ON THE AND HYPERPLASIA OF THE LYMPHATIC LYMPHO-EPITHELIAL ORGANS TISSUES STRENGHTENING IMMUNE DEFENCE Magnesium phosphoricum h 6/12/30/200X D-L Malic Ac./Fumaricum Ac./Pyruvicum Ac. Trychinoil/Natrium oxalac. Stimulation of Lymph flow with stabilization of vessel wall tone with consequent reduction of the exudate and the lymphoedema. Hydrastis 1X Juglans 3X Graphites 6/12/30/200X Inhibition of the proliferative tendencies of the lympho-epithelial tissues Juglans regia 3X 105

106 Kalium sulfuricum 6/8/12X Natrium sulfuricum 6/8/12X Triglyceride hydrolysis stimulation and support in forms of hepatic steatosis*, (hereditary) hypercholesterolemia reduction (Inositol especially)*. Hepatic damage caused by alcohol**. Restoration of metabolic function of the hepatocytes and liver homeostasis***. Ac. Fumaricum 4X* Vit. B1/B2/B3/B6/B12 * Inositol 4X* Cholinum 4X** Natrium oxalaceticum 4X*** Natrium pyruvicum 4X*** Rebalancing of the constitutional weakness of the hepatic subject GUNA-LIVER CONSTITUTIONAL CORE METABOLIC CORE Taraxacum 2X* Carduus 2X* Chelidonium 2X** Ceanothus 6X** DRAINING CORE FUNCTIONAL ACTIVATION CORE Anti-inflammatory and anti-congestive activity on liver and gallbladder*. Stimulation of enzymatic function **. Stimulation of general function of the liver and organs belonging to the digestive system*** Stimulation of hepatic filter function *. Choleretic and cholagogue activity (direct hyperbilirubinemia and icterus)**. Leptandra 6X* Chionanthus 6X* Lycopodium 6X** Hepar suis 6X*** Gal Bladder 8X*** Pancreas suis 8X*** Spleen 8X*** Jejunum p. 8X*** 106

107 Protection of epithelium*. Anti-putrefaction and anti- dysbiosis action **. Vitamin D* 2X Skatolum** 6/10X Regulation of constitutional proneness to drainage insufficiency of the digestive tract. Kali carb. 6/8/12X Natrum carb. 6/8/12X GUNA BOWEL Consitutional rebalance Hepatic stimulation Laxative action Alumina 6/8X Bryonia 6/8X Nux vomica 6/8X Vit. B1 4X, Vit. B3 2X Vit. B5 2X Colon, porc. 6/12/30X Rectum porc. 6/12/30X Stimulation of intestinal function in general. Stimulation of peristalsis. Decrease of rectal atony episodes. Aloe 2X Rhamnus 2X Rheum 2X Reduction of portal stasis*. Choleretic and cholagogue action**. Carduus 2X* Collinsonia 2X* Chelidonium 2X** Taraxacum off. 2X** Laxative action to treat episodes of irritation of intestinal mucosa. 107

108 Renal cell metabolic support Ac. Succinicum 6X Quihynidron 8X Methileneblue 8X GUNA-KIDNEY Solidago 1X* Equisetum 3X* Ononis 2X* Ortosiphon 2X* Sarsaparilla 2X* Mouse ear hawkweed 1X* Plantago 2X** Pareira 2X** Acidum nitricum 6/8/12X*** Kalium nitricum 6/8/12X*** Activation of excretory function of kidney and renal ducts. Diuretic action*. Anti-inflammatory action on renal ducts**. Antidegenerative action on Stimulation of homologous the genital-urinary tract***. organ function. Anti-degenerative action on homologous organs. Kidney 6/8X Ureter 6/8X Urinary bladder 6/8X Colibacillinum 12X Proteus 12X Renal insufficiency secondary to infection Activation of specific immune response in cystitis 108

109 DRAINAGE & DETOXIFICATION DIRECTIONS GUNA MATRIX: 20 drops twice a day for at least 2 months GUNA LYMPHO: 20 dropstwicea day for at least 2 months GUNA CELL: 20 drops twice a day for at least 2 months GUNA KIDNEY: 20 drops twice a day for at least 2 months GUNA LIVER: 5 pellets twice a day for at least 2 months GUNA BOWEL: 20 drops twice a day for at least 2 months ALL THE A.M. PRODUCTS CAN BE TAKEN TOGETHER (for example putting drops of each medicine in 1 litre bottle of water. The patient drinksthis bottle during the whole day)

110 3 CONTROL OF SYMPTOMS Use of specific drugs symptomatically. ( Refer to Guna Method Literature) 110

111 The PRM Therapeutic Triangle P.N.E.I. REPROGRAMMING REMEDY SPECIFIC REMEDY FOR ORGAN OR DISEASE DRAINAGE REMEDY 111

112 P.R.M. in RESPIRATORY DISEASES COLD AND FLU

113 INFLUENZA CITOMIX: 10 granules a week for 6 8 weeks. Repeat the cycle after 45 days GUNA COMPLEX 1: 1 dose a week for 6 8 weeks. Repeat the cycle after 45 days GUNA RHINO NOSE SPRAY: 2 sprays in each nostril twice a day for 2 months COLOSTRO NONI: 1 sachet a day for 1 2 months 113

114 IMMUNESTIMULATION CORE Prevention and treatment of flu and cold syndromes SYMPTOMATIC CORE

115 IMMUNESTIMULATION CORE SINERGISM Subnucleus of Specific Immunity NK Cells Tc Lymphocites Subnucleus of Aspecific Immunity Gamma interferon

116 SYMPTOMATIC REMEDIES CORE Influential myalgia. Antipyretic activity due to heat dispersion (convection). Remedy for the initial phases of the acute fever reaction, with quick, violent and sudden onset. CUPRUM 3C Anas barbariae 200K Influenzinum 9C Vincetoxicum 5C ACONITUM 5C Anti inflammatory and antiseptic action. ECHINACEA 3C BELLADONNA 5C Acute local inflammations, in the initial phase. Evolution of Aconitum symptomatology. t

117 GUNA-COMPLEX 1 GUNA-COMPLEX 1

118 P.R.M. in OTOLARYNGOLOGY Viral Rhinitis Allergic Rhinitis Nasal Polyps Chronic Sinusitis Bacterial Tonsillitis Infectious Mononucleosis Recurrent Tonsillitis Tonsillar Hypertrophy Adenoids Hypertrophy Otitis media

119 Acute GUNA FLAM Inflammation Recurrent GUNA SINUS Nose Spray ENT PATHOLOGIES Sub acute GUNA LYMPHO Hypertrophy Chronic GUNA MATRIX

120 Common cold Viruses Rhinovirus is a RNA virus often associated not only with common cold but also with severe Asthma exacerbation During Rhinovirus infection we have observed: Low levels of IL 10 contributing to unopposed synthesis of pro inflammatory cytokines High levels of IL 12 that may amplify nasal and endobronchial inflammation.

121 VIRAL RHINITIS GUNA FLU 1 dose every 8 hours for 2 3 days GUNA RHINO Nose Spray 2 spray in each nostril 2 3 times a day IL 10 4C drops 2 3 times a day GUNA LYMPHO 20 drops twice a day

122 GUNA RHINO (Nose spray) Argentum nitricum 10X* Rosa canina 1X* Sambucus 2X* Plantago 2X* Apis 6/12/30/200X** Reduction of the mucorespiratory phlogosis* and in particular of the aedema**. Reduction of the phlogosis according to the Histaminum30/200X** oligotherapy*** Cu gluconate 4X*** IL 10 4C**** Hypertonic saline solution ANTI INFLAMMATORY INFLAMMATORY ACTION causing an immediate local reduction of the nasal congestion due to the osmotic effect of the extracellular MEDIUM substance Control of the allergic symptomatology* Modulation of the Th2 activity by means of Th1 with reduction of the IL 4 and IL5 activity** VASOMOTOR SYMPTOMATOLOGY ALLERGIC SYMPTOMATOLOGY Ribes n. MG* Plantago* Euphorbium* Allium cepa 6/8/12X* / Histaminum* IL 12 4C** INF gamma 4C** Stimulation on the Th2/Th3 polarity having antiinflammatory action**** Melilotus 3X Cistus 4X Euphorbium 4X Apis 6/12/30/200X Aralia racemosa 1X Control of the vasal congestion and or hypersecretion phenomena (serous and sero mucous rhinitis)

123 ALLERGIC RHINITIS GUNA ALLERGY ALLERGY GUNA ALLERGY PREV TREAT 20 drops twice a day for 2 20 dropstwicea day for 2 months at least months at least GUNA MATRIX 20 d t i d f 2 20 drops twice a day for 2 months at least IL 12 4C drops twice a day for 2 months at least

124 NASAL POLYPS GUNA FLAM 20 drops twice a day for 2 months at least GUNA SINUS Nose Spray 2 sprays in each nostril 2 3 times a day for 2 monthsat t least GUNA LYMPHO 20 drops twice a day for 2 months at least ANTI IL 1 4C drops 2 3 times a day for 2 months at least

125 SINUSITIS Two types of inflammation occur in sinusitis, contributing variably to the clinical expression of disease. CHRONIC SINUSITIS Allergic component Infectious component IL 5 IL 8

126 CHRONIC SINUSITIS GUNA FLAM 20 drops twice a day for 2 months at least GUNA SINUS Nose Spray 2 sprays in each nostril 2 3 times a day for 2 monthsat t least GUNA LYMPHO 20 drops twice a day for 2 months at least IL 2 4C drops 2 3 times a day for 2 months at least

127 GUNA SINUS (Nose spray) Hypertonic saline solution causing an immediate local reduction of the nasal congestion due to the osmotic effect of the extra cellular substance Argentum nitr. 10X* Plantago 2X* Pulmonaria 2X* Black currant bark MG* Allium cepa 6/8/12X* Echinacea 3X* Pulsatilla 6/8/12X* Urinary bladder. 10/30/200X** Mn-Cu 3X* Vit. C 2X* Antibacterial protection due to the RES stimulation* Hindrance to the infective progression of sinusitis** Echinacea 3x* Thymus gland 6/12/30x* Hepar sulfuris 6/8/12x* Lachesis 12/30/200x** Immune stimulation Secretions drainage Mucosa nasalis 6/12/30x Pulsatilla 6/8/12x Silicea 6/8/112x Secretions fluidification Vicariating drainage towards the nose cave and the pharinx due to centrifugation of the fluidificated secretions Control of the phlogosis signs and symptoms of the respiratory mucosa* Reduction of the sinuses inflammation (in particular frontal sinuses) according to the acupuncture laws Kalium bichromicum 6/8/12x Hydrastis 6/8/12x Cinnabaris 6/8/12x Secretolytic and mucoregulating action. Secretions fluidification, in particular viscous secretions.

128 Bacterial Streptococcus TONSILLITIS Acute Viral Epstein Barr Virus Adenovirus Subacute Actinomycetes Chronic Bacterial

129 BACTERIAL TONSILLITIS CITOMIX 5 10 pellets twice a day GUNA FLAM 20 drops twice a day GUNA LYMPHO 20 dropstwicea day for 2 months at least IL 8 4C drops twice a day

130 RECURRENT TONSILLITIS CITOMIX 5 10 pellets twice a day over an extended period of time (6 7 months) GUNA FLAM drops twice a day over an extended dperiod of time (6 7 months) GUNA LYMPHO drops twice a day over an extended period of time (6 7 months) ANTI IL 1 4C drops 2 3 times a day for 2 months at least

131 GUNA LYMPHO Reduction d i of the local l phlogosis on the lymphoepithelial tissues. Reduction of the lymphatic spasm on inflammatory basis with following restoration of the lymphatic circulation. Calendula 1X Phytolacca 3X Apis 8X Magnesia phosph. h Humoral immunity stimulation and inhibitory modulation of the excessive cell mediated compensatory response Myosotis 3X Equisetum 3X Hydrocotile 1X Taraxacum 1X Sarsaparilla 3X Lymphatic vessel 6X Capillary tisssue 6X L Thyroxin 6/12X Vein porcine 6X REACTIVATION OF THE LYMPHATIC CIRCULATION ANTI INFLAMMATORY INFLAMMATORY HYPERTROPHY AND HYPERPLASY ACTIVITY ON THE OF THE LYMPHATIC ORGANS LYMPHOEPITELIAL TISSUES STRENGHTENING OF THE IMMUNE DEFENCE Magnesium phosphoricum h 6/12/30/200X Juglans regia 3X D L Malic Ac./Fumaricum Ac./Pyruvicum Ac. Trychinoil/Natrium oxalac. Lymphagogue action and stabilization of the vasal walls tone with consequent reduction of the extudate and the lymphoedema. Hydrastis 1X Juglans 3X Graphites 6/12/30/200X Hindrance to the proliferative proneness of the lymphoepitelial tissues

132 RECURRENT INFECTIONS Th1 Response LYMPHATIC ENLARGEMENT Th2 Response

133 TONSILLAR HYPERTROPHY CITOMIX 5 10 pellets twice a day over an extended period of time (6 7 months) GUNA LYMPHO drops twice a day over an extended period of time (6 7 months) GUNA MATRIX dropstwicea day over an extended period of time (6 7 months) IFN γ 4C drops 2 3 times a day for 2 months at least

134 ADENOIDS HYPERTROPHY CITOMIX 5 10 pellets twice a day in acute phase (10 15 days) GUNA SINUS Nose Spray 2 spray in each nostril 2 3 times a day for 2 months at least GUNA MATRIX dropstwicea day over an extended period of time (4 5 months) IFN γ 4C drops 2 3 times a day for 2 months at least

135 Pyrogenium 12X* Fucus 3X* Tyrosine T i 2X** Phenilalanine 2X** Histidine 2X** Deactivation (through inflammation) and neutralization of the impregnation toxins*. Synergic action with Fucus of the thyroid hormons activating the sympatheticotonic nervous system**. Hyaluronidase 6X* Thuja 6/8/12/30/200X** Natrium N t i sulfuricum 6/8/12/30/200X ** Prolactine 6X*** DHEA 6X*** Matrix hydrolysis* y Action against the constitutional proneness to a matrix impregnation and to the development of a Dysmetabolic Mesenchymopathy (Sycosis).** Matrix solubilization.*** GUNA MATRIX Action against toxin impregnation Lymphatic drainage Lymphatic vessel 6X Matrix drainage Inactive toxins canalization towards the lymphatic circle for the drainage Ac. D-L malicum 6X* Natrium oxal. 6X* Natrium pyruv. 6X* NADID 6X* Trychinoil 6X* Vit. C 2X* Ac. L(+) lacticum3x** Stimulation l of the energetic mitochondrial activity.* Matrix acidification (promoting the connective reactivity).** IL 6 4C* DHEA 6X* Pyrogenium 12X* Conjunctive Tissue 6X* Tyrosine 2X** Phenilalanine 2X** Histidine 2X** Prolactine 6X*** Increase of the Fundamental Substance cynetics (protein hydrolysis, hyper ionicity, histaminic activity, > temperature) and of the matrix turnover.* Sympatheticotonic stimulation.** Vagotonic slowdown.***

136 OTITIS MEDIA CITOMIX GUNA FLAM 5 10pellets twice a dayin dropsevery acute phase; in prevention: minutes for 2 3 hours in acute 5 10 pellets once a day phase; then drops twice over an extended period of a day time (2 3 months) GUNA LYMPHO dropstwicea day over an extended period of time (4 5 months) IL 12 4C drops twice a day for 2 months at least

137 RRI (Recurrent Respiratory Infections) CITOMIX: 10 granules a week for 6 8 weeks. Repeat the cycle after 45 days GUNA FLU: 1 dose a week for 6 8 weeks. Repeat the cycle after 45 days GUNA BOWEL: 20 drops twice a day for 2 4 months GUNA LYMPHO: 20 drops twice a day for 2 4 months COLOSTRO NONI: 1 sachet a day for 1 2 months 137

138 MAIN THERAPEUTIC PROTOCOLS IN YOUR DAILY PRACTICE 138

139 THERAPEUTIC PROPOSAL FOR CANCER INF gamma 4CH: 20 drops twice a day for 2 4 months (to stimulate CD8+ cells) + Il 12 4CH: 20 drops twice a day for 2 4 months (to stimulate CD8+ cells) GUNA RERIO: 40 3 times a day for very long time COLCHICUM COMP (HEEL) SOMATOSTATINE 4CH: 20 drops twice a day for 2 4 months + GUNA MATRIX: 20 drops MELATONIN 4CH: 20 drops twice a day for 2 4 months twice a day for 2 4 months (to + inhibit GH) GUNA CELL: 20 drops twice a day for 2 4 months 139

140 GUNA-RERIO GUNA RERIO INDUCTION SUPPRESSION ONCOGENIC SUPPRESSORS ONCOGENS P.M. Biava, A. Carluccio Attivazione dell antioncogene p53 su differenti tipi di cellule tumorali in vitro a seguito del trattamento con estratti embrionari purificati in diversi stadi di differenziamento cellulare. La Medicina Biologica 1997/2 supplemento

141 Cytokinic structure Autoimmune Thyroiditis IL 6 IL 12 Increase of IFN γ IL 8 HASHIMOTO S THYROIDITIS IL 1 IL 10 Relative deficiency of IL 4 IL 2

142 AUTOIMMUNE DISEASES Hashimoto Disease (TSH over 3 not treated with Eutirox) Excess of IL17/IL2/IL5/IL6 Low level of: IL4 IL4 4CH: 20 drops twice a day for 4 6 months + T4 D6: 20 drops twice a day for 4 6 months + T3 D6: 20 drops twice a day for 4 6 months GLANDULA THYREOIDEA SUIS INJEEL: 1 ampoule a week for 4 6 months GUNA MATRIX: 20 drops twice a day for 4 6 months 142

143 RHEUMATOID ARTHRITIS IMMUNOLOGICAL HYPERACTIVATION Pathologic inflammatory status Physiological antiinflammatory response Inhibitory therapy of hyperexpressed cytokines with Anti IL 1 4C Boosting of this stimulus TGF β 4C IL 10 4C Prof. Ivo BIANCHI 143

144 AUTOIMMUNE DISEASES RHEUMATOID ARTHRITIS (Theoretical) Excess of IL1, IL6, IL2, TNF α, IL17 ANTI IL1: 20 drops twice a day for 2 4 months + IL4 4CH: 20 drops twice a day for 2 4 months + IL10 4CH: 20 drops twice a day for 2 4 months GUNA FLAM: 20 drops twice a day for 2 4 months GUNA POLYARTHRITIS (injectable therapy) : according to the Pain Management protocols GUNA MATRIX: 20 drops twice a day for 2 4 months 144

145 CROHN DISEASE Excess of IL12, IL6, TNF α; IL18 IL10 4CH: 20 drops twice a day for 4 6 months ANTI IL1: 20 drops twice a day for 4 6 months IL4 4CH: 20 drops twice a day for 4 6 months GUNA MOOD: 20 drops twice a day for 4 6 months COLOSTRO NONI: 2 sachets a day for 1 2 months GUNA FLAM: 20 drops twice a day for 4 6 months GUNA BOWEL: 20 drops twice a day for 4 6 months 145

146 PSORIASIS Excess of IL1α and β, IL8, IL6, IL12, IL 23, IL2, INF α, IL17 IL4 4CH: 20 drops twice a day for 4 6 months + IL10 4CH: 20 drops twice a day for 4 6 months + IL11 4CH: 20 drops twice a day for 4 6 months GUNA MOOD: 20 drops twice a day for 2 4 months GUNA LIVER: 20 drops twice a day for 2 4 months + GUNA CELL: 20 drops twice a day for 2 4 months (or ACIDUM FUMARICUM INJEEL FORTE: 1 ampoule per os twice a week for 4 6 months) TAMANU ARNICA: a thin coat of cream on the affected areas twice a day 146

147 Excess of IL1, IL2, IL6, TNF α Necessity to stimulate α MSH VITILIGO IL4 4CH: 20 drops twice a day for 4 6 months + IL10 4CH: 20 drops twice a day ANTI AGE SKIN: 5 pellets 2 3 for 4 6 months times a day for 4 6 months + IFN α 4CH: 20 drops twice a day for 4 6 months (it is able to stimulate MSH through the irritation of melanocites) GUNA CELL: 20 drops twice a day for 4 6 months) NT4 4CH: 20 drops twice a day for 4 6 months NGF 4CH: 20 drops twice a day for 4 6 months GUNA MOOD: 20 drops twice a day for 2 4 months 147

148 Cytokinic structure in SLE IL 6 Increase of IL 10 INF gamma SLE IL 5 (?) Partial decrease of TNF α

149 SLE (Systemic Lupus Erythematosus) GUNA MALE GUNA FLAM 20 drops twice a day over 20 drops twice a day over extended dd periods of time extended periods of time (4 5 (4 5 months) months) GUNA MATRIX 20 drops twice a day over extended periods of time (4 5 months) TNF alfa 4C 10 drops twice a day over extended periods of time (4 5 months)

150 IL 12 Pathogenetic interleukins TNF α MS IL 4 (Multiple Sclerosis) Protective Interleukins IL 10 TGF ββ

151 MULTIPLE SCLEROSIS GUNA MALE 20 drops twice a day over extended periods of time GUNA MATRIX 20 drops twice a day over extended periods of time GUNA CELL 20 drops twice a day over extended periods of time TGF β β 4C 20 drops 3 times a day over extended periods of time

152 CHRONIC PROSTATITIS CITOMIX: 5 granules a day for 6 8 weeks. Repeat the cycle after 45 days GUNA PROSTATE: 20 drops twice a day for 2 4 months GUNA CELL: 20 drops twice a day for 2 4 months GUNA LYMPHO: 20 drops twice a day for 2 4 months 152

153 GUNA-PROSTATE Control of inflammatory events and proliferative processes Control of inflammatory events* and proliferative processes** (through IL-10 4C* stimulation of apoptosis TGF-ß 1 4C* secondary to the activation Melatonin 4C* of CD + 8) IFN-γ 4C** IL-2 4C*** Anti-aging g g activity*** Prostate porcine 200X Endocrine regulation acc. to oligotherapy. ORGANOTHERAPIC CORE P.N.E.I. CORE CELL NUTRITIONAL SUPPORT CORE HOMEOPATHIC CORE Thuja occ 12/30X Clematis erecta 3X Selenium met 12/30X Chimaphila umb. 6X Baryta carbonica 12/30X Sabal serrulata 3X Conium mac. 12/30X Digitalis purp. 12/30X Ferrum picricum 12/30X Staphisagria 12/30X Agnus castus 6X Control C t l of inflammatory events and proliferative processes Nutrient fot the prostate Zincum met. 3X Support of the sexual functions

154 Citokines Hormones CH 4 Guna Prostate Interleukin 10 Interferon gamma Transforming Interleukin 2 Melatonin Growth factor beta Suis-Organ D200 Homeopathic remedies D30 D12 D6 D3 Mineral Herbal remedies Zn Chimaphila hil Baryta Conium umbellata carbonica Staphysagria Selenium Sabal Agnus Thuja Digitalis serrulatum castus Ferrum picrinicum Prostata Clematis

155 PRM SEXUAL WELLNESS 155

156

157

158

159

160

161 Recovery of perfect homeostasis with the GUNA METHOD

162 WELLNESS THERAPY according to PRM WITH RESPECT TO PHYSIOLOGY HYDROLYSIS OF MATRIX PROTEINS PROTEASE ACTIVITY MATRIX REMODELLING SOLID PHASE INCREASE OF TEMP HISTAMINE ACTIVITY MYELOID TENDENCY SYMPATHETICOTONYS O ACIDOSIS ACIDOSIS 1. Drainage 2. P.N.E.I. rebalance ALKALOSIS RE SYNTHESIS OF MATRIX PROTEINS ANTI PROTEASE ACTIVITY REBUILDING OF MATRIX GEL PHASE DECREASING OF TEMP LYMPHOID TENDENCY VAGOTONY ALKALOSIS 3. Neuro vegetative rebalance 4. ph rebalance

163 WELLNESS THERAPY according to PRM WITH RESPECT TO PHYSIOLOGY Every day for at least 2 months 1 GUNA MATRIX, 40 drops + GUNA LYMPHO, 40 DROPS + GUNA CELL, 40 drops + 2 GUNA FEM/GUNA MALE, 40 drops ALL THE A.M. PRODUCTS CAN BE TAKEN TOGETHER (for example putting drops of each medicine in 1 litre bottle of water. The patient drinks this bottle during the whole day, or 20 drops of each twice daily) 3 + GUNA TONIC, 20 ml (at 9:00 a.m.) + MELATONIN 4CH, 20 drops (at 9:00 p.m.) )(GUNA SLEEP) + 4 GUNA BASIC 1 bag (at 9:00 pm) p.m.) 1) Drainage 3) Neuro vegetative rebalance bl 2) P.N.E.I. rebalance 4) ph rebalance

164 Da: PsicoNeuroEndocrinoImmunologia. Francesco Bottaccioli RED Edizioni

165 CEREBRAL CORTEX AMIGDALA HYIPPOCAMPUS STRESS Eu stress Di stress HYIPOTALAMUS CRH HYPOPHYISIS ACTH LOCUS COERULEUS SYMPATETHIC SYSTEM NORADRENALINA ADRENAL CORTEX ADRENAL M. CORTISOL ADRENALIN 165

166 GU UNA T TON NIC

167 Synchronization of circadian rythyms*. Stimulation of the hypothalamic sleep core**. GUNA-SLEEP Ignatia Serotonin Melissa Valeriana Avena sativa Serotonina* Melatonina* Pineal Gland* IL 1** HYPNO- INDUCING CORE Increased anxiety tolerance. Sensitization of Serotonin receptors with inibitory- like effect on re-uptake activity. Hypno-inducing action secondary to a reduction of anxiety & restlessness. Helleborus Chamomilla Melissa Avena sativa

168 MELATONIN 4CH MELATONIN 4CH STIMULANT FOR THE PRODUCTION OF THE BRAIN S OWN MELATONIN AND SENSITIZATION OF MELATONIN RECEPTORS

169 GU UNA B BAS SIC

170 GU UNA B BASIC

171 PRM FUNCTIONAL DISORDERS 171

172 AUTISM (complementary therapy) GUNA FEM/MALE: 20 drops twice a day for 2 4 months + BDNF 4CH: 20 drops at evening every day for 2 4 months GUNA AWARENESS: 20 drops twice a day for 2 4 months GUNA MATRIX: 20 drops twice a day for 2 4 months + GUNA LYMPHO: 20 drops twice a day for 2 4 months + GUNA CELL: 20 drops at evening every day for 2 4 months + EUBIOFLOR: 20 drops at evening every day for 2 4 months 172

173 Citokines Hormon CH 4 Guna Awareness NT3 NT4 BDNF Melatonin Neuro transmitter Hormones Homeopathic remedies Suis-Organs D12 D6 D3 Minerals Vitamins Catalyst Zn Cr Mb Vitamina B12 Ubichinon TRH Silicea Aurum metallicum Lobo frontalis Va Fe Ca Acido folico Ossitocina Trimetilglicina Zincum metallicum Cicuta virosa Lachesis Rana bufo Cuprum metallicum Lobo temporalis

174 VINNIE WAS BROUGHT TO MY OFFICE BY HIS PARENTS; HE WAS TWELVE AND HAS HAD SEVERE AUTISM FIRST OBSERVED AT ABOUT TWO YEARS OLD. VINNY IS TALL, THIN,WITH DARK HAIR AND OLIVE SKIN. IT THE EXAM ROOM VINNY SAT IN HIS OWN WORLD. NEITHER REACTING TO OR JOINING IN THE CONVERSATION HE WOULD PERIODICALLY MAKE A COMMENT THAT NO ONE COULD FOLLOW. HIS PARENTS FEEL HIS AUTISM WAS A RESULT OF THE VACCINATION GIVEN TO HIM AT BIRTH. WE STARTED HIM ON A PROTOCOL OF: GUNA AWARENESS GUNA MOOD GUNA KIDNEY GUNA LYMPHO GUNA MATRIX GUNA CELL THE DOSAGE IS TEN DROPS OF EACH, THREE TIMES DAILY I INFORMED THE PARENTS THAT I COULD NOT MAKE ANY PROMISES DUE TO HIS AGE AND HOW LONG THE PROBLEM HAS BEEN GOING ON. I ALSO INFORMED THAT HE SHOULD STAY WITH THE TREATMENT FOR AT LEAST 90 DAYS. AT THE END OF 90 DAYS I WAS SURPRISED TO FIND HIS FATHER AND BOTH OF HIS GRAND MOTHERS IN MY OFFICE. THEY WERE VERY EXCITED AND WANTED TO SHARE VINNY S PROGRESS WITH ME. IT SEEMS THAT VINNY IS NOW SPEAKING IN FULL SENTENCES AND IS GETTING STRAIGHT A's IN SCHOOL. HIS GRANDMOTHER WAS IN TEARS WHEN SHE RELATED THE EXPERIENCE OF TAKING VINNY TO A AMUSEMENT PARK AND GOING ON A ROLLER COASTER TOGETHER. SHE SAID THAT VINNY REACHED OUT AND TOUCHED HER SHOULDER AND SAID"THIS RIDE IS MAGNIFICENT" IT WAS THE FIRST TIME THAT HE HAD EVER TOUCHED HER ON HIS OWN. WE ARE GOING TO KEEP VINNY ON THE MEDS FOR AS LONG AS HE CONTINUES TO IMPROVE. THIS RESULT WAS ACHIEVED WITH ORAL MEDS. ALONE. NO ACUPUNCTURE WAS USED IN CONJUNCTION WITH THE MEDS. RESPECTFULLY DR. omissis

175 METABOLIC SYNDROME 1.Central Obesity 2.High blood pressure 3.High tryglycerides 4.Low HDL cholesterol 5.Insulin resistance

176 METABOLIC SYNDROME About Insulin resistance we can do some reasonings. As you know, insulin and GH are realated each other, it means that if you have high levels of GH you increase the amount of insulin in the blood. But we know that with a negative feedback, IGF 1 is able to slowing down the production of GH. So, our IGF 1 4CH could be good. Consider also to slow down GH the use of Somatostatine 4 CH From the point of view of interleukins it is important to reduce the pro inflammatory ones (IL 6 especially but IL 1 and TNF alfa also) for instance using the opposite cytokines like IL 10 and IL 4. It is important to drain the matrix because the problem is that insulin molecules don't arrive to the membrane receptor of the the cell's: Guna Matrix Add Guna Cell also. Use absolutely Guna Liver, because you know that insuline resistance provoke an increase of LDL and a deacrease of HDL. Guna Liver works very well in these conditions. Reduce stress (cortisol mobilize insuline). To control cortisol we can suggest T3 6X to slowing down cortsicosteroids activity And use SON Formula.

177 INSULIN RESISTENCE METABOLIC SYNDROME Somatostatin 4CH GUNA MATRIX HYPER INSULINEMIA Cortisolo Stress SON Formula HYPERGLICEMIA. THE EXCESS OF SUGAR IS TRANSFORMED IN FAT T4 D6 Insulin resistance modifies fat metabolism: INCREASE OF LDL/REDUCTION OF HDL AT LEVER LEVEL Ω Formula/Guna Liver OBESITY SON Formula HYPERTROPHIC FAT CELLS ATEROSCLEROSYS cholesterol level increased pro inflammatorystimuli (IL 6, TNF α) fat hyperoxidative processes Ω Formula IL 10 4CH Ω Formula

178 METABOLIC SYNDROME 1.Central Obesity SON Formula/T4 6X 2.High blood pressure Guna Hypertension 3.High tryglycerides y Ω Formula/Guna Liver 4.Low HDL cholesterol 5.Insulin resistance Ω Formula/Guna Liver Somatostatin 4C/Guna Matrix